Related Experiment Videos
[Vaccination of the immunocompromised host]
Andrew J Ullmann1, Meinolf Karthaus, Oliver A Cornely
1III. Medizinische Klinik und Poliklinik, Klinikum der Johannes Gutenberg-Universität, Mainz, Deutschland. ullmann@3-med.klinik.uni-mainz.de
Wiener Medizinische Wochenschrift (1946)
|July 13, 2004
Summary
Vaccinations are safe and effective for immunocompromised patients, though often underutilized. Key vaccines like influenza, pneumococcal, and meningococcal are recommended, with live vaccines generally contraindicated.
Area of Science:
- Immunology
- Infectious Diseases
- Oncology
Context:
- Immunocompromised patients, including those with cancer, face increased infection risks.
- Vaccine underutilization is prevalent in this vulnerable population.
- Specific B-cell deficiencies warrant particular immunization considerations.
Purpose:
- To review current vaccination recommendations for immunocompromised individuals.
- To highlight the safety and efficacy of vaccinations in this group.
- To emphasize the need for consistent immunization practices in cancer patients.
Summary:
- Vaccinations are generally safe and effective in immunocompromised patients.
- Recommended vaccines include influenza, diphtheria, tetanus, pneumococcal, meningococcal, and Haemophilus influenzae type B.
- Live attenuated vaccines are typically contraindicated, and antibody response may be reduced.
Impact:
- Consistent immunization practices can significantly benefit immunocompromised cancer patients.
- Increased vaccine uptake can reduce infection-related morbidity and mortality.
- Further clinical trials are essential to optimize vaccination strategies.